Microbot Medical INC 8-K filings

Microbot Medical Inc. announced the commercial debut of its LIBERTY Endovascular Robotic System at a major medical meeting following FDA 510(k) clearance and completed hiring of its commercial leadership team.

Microbot Medical partners with a U.S. 3PL for the commercial launch of its FDA-cleared LIBERTY Endovascular Robotic System.

Microbot Medical Inc. announced the final closing of its preferred investment option exercises, raising $29.2 million in gross proceeds with potential for an additional $63 million.

Microbot Medical Inc. announced the exercise of 600,000 preferred investment options, the issuance of 600,000 new Series J options, and raised approximately $896,000 from other option exercises.

Microbot Medical Inc. announced the Japanese Patent Office granted its first patent for the core LIBERTY System technology, expanding its global intellectual property portfolio.

Microbot Medical's CEO, Harel Gadot, will discuss the recent FDA clearance of its LIBERTY Endovascular Robotic System and U.S. commercialization plans in an upcoming interview.

Microbot Medical Inc. granted one-time cash bonuses to executive officers and non-management board members, partially compensating for prior salary waivers.

Microbot Medical Inc. announced an inducement transaction raising $29.2 million from existing preferred investment option exercises, with potential for an additional $63 million from new Series J preferred investment options.

Microbot Medical Inc. announced the release of updated investor presentation materials and its participation in the H.C. Wainwright Annual Investor Conference.

Microbot Medical Inc. announced FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, paving the way for U.S. commercialization.

Microbot Medical Inc. announced it generated approximately $8.6 million in gross proceeds through the exercise of preferred investment options, leading to the issuance of 4,055,870 common shares.

Microbot Medical Inc. announced the issuance of approximately 3 million common shares, generating $5.9 million in gross proceeds from the exercise of various preferred and incentive options.

Microbot Medical Inc. announced a new U.S. patent for its modular robotic surgical system, significantly expanding the potential market for its LIBERTY device.

Microbot Medical Inc. announced the exercise of Series G preferred investment options generating $7.6 million and approval for a NIS 2.15 million non-dilutive grant from the Israel Innovation Authority to enhance operational capabilities.

Microbot Medical Inc. announced the issuance of 2,395,715 common shares, generating approximately $4.2 million in gross proceeds from the exercise of Series G preferred investment options.

Microbot Medical Inc. announced the appointment of Christina Bailey, a seasoned medical device sales executive, as its new Vice President of Sales to bolster commercial efforts for its innovative LIBERTY Endovascular Robotic System.

Microbot Medical Inc. announced the exercise of Series G and Series F preferred investment options, generating approximately $2.975 million in gross proceeds.

Microbot Medical Inc. announced its participation and leadership in the inaugural Endovascular Robotics session at the Society of Robotic Surgery annual meeting, while also preparing for the U.S. launch of its LIBERTY system pending anticipated FDA 510(k) clearance this quarter.

Microbot Medical Inc. announced its inclusion in the Russell Microcap Index, effective June 30, 2025, a strategic move expected to enhance its market visibility as it prepares for the anticipated Q3 2025 launch of its LIBERTY Endovascular Robotic System.

Microbot Medical Inc. announced the grant of a critical patent in China for its LIBERTY Endovascular Robotic System, further strengthening its global intellectual property portfolio and supporting its long-term commercial strategy ahead of an anticipated Q3 2025 U.S. commercial launch.

Microbot Medical Inc. announced that its stockholders approved a significant increase in authorized common stock to 120 million shares and made previously issued investment options immediately exercisable following the 2025 Annual Meeting.

Microbot Medical Inc. announced the expansion of its commercial team with a new head of Sales Operations & Analytics and updated the expected FDA 510(k) decision for its LIBERTY Endovascular Robotic System to Q3 2025, which remains within the original review window and is not expected to impact the planned launch.

Microbot Medical Inc. announced its preliminary selection for inclusion in the Russell Microcap Index, a move expected to enhance its visibility among institutional investors.

Microbot Medical Inc. announced the release of updated presentation materials on April 30, 2025, which will be available on its website.

Microbot Medical announces new leadership hires and the issuance of common stock upon the exercise of preferred investment options.

Microbot Medical will re-propose two proposals at its annual meeting on June 10, 2025, after a planned special meeting on April 11, 2025, failed to achieve a quorum.

Microbot Medical Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings from a majority to one-third of the votes entitled to be cast, effective immediately on April 14, 2025.

Microbot Medical reports 100% success in robotic navigation and a 92% reduction in radiation exposure in its ACCESS-PVI pivotal trial using the LIBERTY Endovascular Robotic System.

Microbot Medical announces the presentation of ACCESS-PVI trial data at the Society of Interventional Radiology Annual Meeting and reaffirms its expectation for FDA's 510(K) clearance decision on the LIBERTY system in the current second quarter.

Microbot Medical hires Paul Mullen as VP of Sales to lead U.S. commercialization efforts for the LIBERTY Endovascular Robotic System, anticipating FDA clearance in Q2 2025.